ResearcherID - CLICK HERE

TITLE:

ANALYSIS OF BLOOD PRESSURE MEASUREMENT AND TREATMENT OF HYPERTENSION IN PAKISTAN

AUTHORS:

Dr Syed Basit Azeem, Dr Mohsin Maqsood, Dr Anum Yamin

ABSTRACT:

Introduction: Hypertension is a modifiable and major risk factor for coronary artery disease, heart failure, cerebrovascular disease and chronic renal failure. It is also recognized as a global chronic, non-communicable disease and a “silent killer” due to its high mortality rates and lack of early symptoms. Objectives of the study: The main objective of the study is to analyze the blood pressure measurement and treatment of hypertension in Pakistan. Methodology of the study: This cross sectional study was conducted at DHQ hospital Narowal during January 2018 to October 2018. All patients older than 18 years were included in the study. For this study a standard questionnaire was used to collect medical history from each patient. Age, sex, marital status, education, work history, smoking, alcohol intake, and physical activity level were recorded. Patients were also asked about personal and family history of hypertension, diabetes mellitus, cardiovascular disease, and chronic kidney disease. Blood pressure measurements were performed using a mercury sphygmomanometer for patients seated for 5 min with the arm positioned at heart level. Results: Demographic values and treatment of hypertension has direct relationship. As there are many factors which are responsible for medication and treatment in a country like Pakistan. Table 01 explains the demographic values of all male and female patients. Conclusion: It is concluded that there is a difference between standard BP treatments which affect the decision to start medication and the decision to initiate treatment, but not the decision regarding alteration of regime for those already on treatment. Key words: Blood, Hypertension, risk, Hypertensive

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.